作者: Susan M. Keating , D. Lansing Taylor , Anne L. Plant , E. David Litwack , Peter Kuhn
DOI: 10.1111/CTS.12536
关键词: Validation Studies as Topic 、 Data science 、 Tumor heterogeneity 、 Cellular level 、 Patient care 、 Government 、 Data integration 、 Computer science 、 Single-cell analysis 、 Neoplasms diagnosis
摘要: The high-content interrogation of single cells with platforms optimized for the multiparameter characterization in liquid and solid biopsy samples can enable heterogeneous populations ex vivo. Doing so will advance diagnosis, prognosis, treatment cancer other diseases. However, it is important to understand unique issues resolving heterogeneity variability at cell level before navigating validation regulatory requirements order these technologies impact patient care. Since 2013, leading experts representing industry, academia, government have been brought together as part Foundation National Institutes Health (FNIH) Biomarkers Consortium foster potential data integration clinical translation.